ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

dupilumab

Also written as “Dupilumab”, “Dupilumab SAR231893” and “Dupilumab (SAR231893)”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Eosinophilic Esophagitis · Nasal Polyps · Pulmonary Disease, Chronic Obstructive, led by 3 companies.

Drug pageDupilumab: every studyAll 180 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 16, 201993 company-led studies, 14 open or runningNext primary completion: Feb 7, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofiits history only529 open or runningphase 4since Jul 16, 2019Mar 9, 2011Feb 7, 2027phase 4 · NCT07905547
Regeneron Pharmaceuticalsits history only404 open or runningphase 4since Dec 17, 2019Nov 10, 2009Apr 24, 2027phase 4 · NCT06572228
Andover Eye Associates11 open or runningphase 2since Mar 2, 2020Mar 2, 2020none ahead

Also a collaborator on its studies: Aimmune Therapeutics and Statistics & Data.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Andover Eye Associates only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 2, 2020First study: phase 2 study in Atopic KeratoconjunctivitisFirst studyNCT04296864 · 42 planned · United States

TargetBeta

IL4R →read by rule
“Interleukin-4 receptor subunit alpha antagonist”ChEMBL 37, by rule

Other programs on IL4R

ProgramCompanyFurthest phaseStudies
drotokibartJiangsu HengRui Medicinephase 38
TQH2722Sino Biopharmaceuticalphase 37
SHR-1819Jiangsu HengRui Medicinephase 35

Studies

The one study Andover Eye Associates leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04296864Atopic Keratoconjunctivitis · United States2RecruitingJan 202542

How it is read

Names in the registry

  • “Dupilumab”, 55 entries
  • “Dupilumab SAR231893”, 13 entries
  • “dupilumab”, 10 entries
  • “Dupilumab (SAR231893)”, 5 entries
  • “REGN668”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.